138 related articles for article (PubMed ID: 33969806)
1. Synergistic effects of BKM120 and panobinostat on pre-B acute lymphoblastic cells: an emerging perspective for the simultaneous inhibition of PI3K and HDACs.
Mehrpouri M; Momeny M; Bashash D
J Recept Signal Transduct Res; 2022 Feb; 42(1):100-108. PubMed ID: 33969806
[TBL] [Abstract][Full Text] [Related]
2. Abrogation of histone deacetylases (HDACs) decreases survival of chronic myeloid leukemia cells: New insight into attenuating effects of the PI3K/c-Myc axis on panobinostat cytotoxicity.
Zehtabcheh S; Yousefi AM; Salari S; Safa M; Momeny M; Ghaffari SH; Bashash D
Cell Biol Int; 2021 May; 45(5):1111-1121. PubMed ID: 33501756
[TBL] [Abstract][Full Text] [Related]
3. Anti-leukemic effects of histone deacetylase (HDAC) inhibition in acute lymphoblastic leukemia (ALL) cells: Shedding light on mitigating effects of NF-κB and autophagy on panobinostat cytotoxicity.
Mehrpouri M; Safaroghli-Azar A; Pourbagheri-Sigaroodi A; Momeny M; Bashash D
Eur J Pharmacol; 2020 May; 875():173050. PubMed ID: 32142770
[TBL] [Abstract][Full Text] [Related]
4. PI3K Abrogation Using Pan-PI3K Inhibitor BKM120 Gives Rise to a Significant Anticancer Effect on AML-Derived KG-1 Cells by Inducing Apoptosis and G2/M Arrest.
Sadeghi S; Esmaeili S; Pourbagheri-Sigaroodi A; Safaroghli-Azar A; Bashash D
Turk J Haematol; 2020 Aug; 37(3):167-176. PubMed ID: 32160736
[TBL] [Abstract][Full Text] [Related]
5. Anticancer effect of pan-PI3K inhibitor on multiple myeloma cells: Shedding new light on the mechanisms involved in BKM120 resistance.
Safaroghli-Azar A; Bashash D; Kazemi A; Pourbagheri-Sigaroodi A; Momeny M
Eur J Pharmacol; 2019 Jan; 842():89-98. PubMed ID: 30401630
[TBL] [Abstract][Full Text] [Related]
6. Pan-HDAC inhibitor panobinostat, as a single agent or in combination with PI3K inhibitor, induces apoptosis in APL cells: An emerging approach to overcome MSC-induced resistance.
Mosleh M; Safaroghli-Azar A; Bashash D
Int J Biochem Cell Biol; 2020 May; 122():105734. PubMed ID: 32119989
[TBL] [Abstract][Full Text] [Related]
7. Anti-leukemic effect of PI3K inhibition on chronic myeloid leukemia (CML) cells: shedding new light on the mitigating effect of c-Myc and autophagy on BKM120 cytotoxicity.
Shiri Heris R; Safaroghli-Azar A; Yousefi AM; Hamidpour M; Bashash D
Cell Biol Int; 2020 May; 44(5):1212-1223. PubMed ID: 32068318
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of PI3K pathway using BKM120 intensified the chemo-sensitivity of breast cancer cells to arsenic trioxide (ATO).
Alipour F; Riyahi N; Safaroghli-Azar A; Sari S; Zandi Z; Bashash D
Int J Biochem Cell Biol; 2019 Nov; 116():105615. PubMed ID: 31539632
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of PI3K signaling pathway enhances the chemosensitivity of APL cells to ATO: Proposing novel therapeutic potential for BKM120.
Bashash D; Delshad M; Riyahi N; Safaroghli-Azar A; Pourbagheri-Sigaroodi A; Momeny M
Eur J Pharmacol; 2018 Dec; 841():10-18. PubMed ID: 30316766
[TBL] [Abstract][Full Text] [Related]
10. Novel pan PI3K inhibitor-induced apoptosis in APL cells correlates with suppression of telomerase: An emerging mechanism of action of BKM120.
Bashash D; Delshad M; Safaroghli-Azar A; Safa M; Momeny M; Ghaffari SH
Int J Biochem Cell Biol; 2017 Oct; 91(Pt A):1-8. PubMed ID: 28834761
[TBL] [Abstract][Full Text] [Related]
11. Inhibitor of pan class-I PI3K induces differentially apoptotic pathways in acute leukemia cells: Shedding new light on NVP-BKM120 mechanism of action.
Bashash D; Safaroghli-Azar A; Delshad M; Bayati S; Nooshinfar E; Ghaffari SH
Int J Biochem Cell Biol; 2016 Oct; 79():308-317. PubMed ID: 27599915
[TBL] [Abstract][Full Text] [Related]
12. Molecular effects of the phosphatidylinositol-3-kinase inhibitor NVP-BKM120 on T and B-cell acute lymphoblastic leukaemia.
Pereira JK; Machado-Neto JA; Lopes MR; Morini BC; Traina F; Costa FF; Saad ST; Favaro P
Eur J Cancer; 2015 Sep; 51(14):2076-85. PubMed ID: 26238016
[TBL] [Abstract][Full Text] [Related]
13. ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma.
Yun MR; Choi HM; Kang HN; Lee Y; Joo HS; Kim DH; Kim HR; Hong MH; Yoon SO; Cho BC
Oncogene; 2018 Jan; 37(3):377-388. PubMed ID: 28945228
[TBL] [Abstract][Full Text] [Related]
14. The phosphatidylinositol-3-kinase inhibitor NVP-BKM120 overcomes resistance signals derived from microenvironment by regulating the Akt/FoxO3a/Bim axis in chronic lymphocytic leukemia cells.
Rosich L; Saborit-Villarroya I; López-Guerra M; Xargay-Torrent S; Montraveta A; Aymerich M; Villamor N; Campo E; Pérez-Galán P; Roué G; Colomer D
Haematologica; 2013 Nov; 98(11):1739-47. PubMed ID: 23850807
[TBL] [Abstract][Full Text] [Related]
15. Subcellular localization of FOXO3a as a potential biomarker of response to combined treatment with inhibitors of PI3K and autophagy in PIK3CA-mutant cancer cells.
Kim HJ; Lee SY; Kim CY; Kim YH; Ju W; Kim SC
Oncotarget; 2017 Jan; 8(4):6608-6622. PubMed ID: 28036259
[TBL] [Abstract][Full Text] [Related]
16. Histone Deacetylase Inhibitors as Multitarget-Directed Epi-Drugs in Blocking PI3K Oncogenic Signaling: A Polypharmacology Approach.
Ranganna K; Selvam C; Shivachar A; Yousefipour Z
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33147762
[TBL] [Abstract][Full Text] [Related]
17. Molecular mechanisms underlying the clinical efficacy of panobinostat involve Stochasticity of epigenetic signaling, sensitization to anticancer drugs, and induction of cellular cell death related to cellular stresses.
El Omari N; Bakrim S; Khalid A; Abdalla AN; Almalki WH; Lee LH; Ardianto C; Ming LC; Bouyahya A
Biomed Pharmacother; 2023 Aug; 164():114886. PubMed ID: 37224752
[TBL] [Abstract][Full Text] [Related]
18. Synergistic Antitumor Effect of BKM120 with Prima-1Met Via Inhibiting PI3K/AKT/mTOR and CPSF4/hTERT Signaling and Reactivating Mutant P53.
Li Z; Xu X; Li Y; Zou K; Zhang Z; Xu X; Liao Y; Zhao X; Jiang W; Yu W; Guo W; Chen Y; Li Y; Chen M; Deng WG; Li L; Zou L
Cell Physiol Biochem; 2018; 45(5):1772-1786. PubMed ID: 29495002
[TBL] [Abstract][Full Text] [Related]
19. Effects of PI3K inhibitor NVP-BKM120 on overcoming drug resistance and eliminating cancer stem cells in human breast cancer cells.
Hu Y; Guo R; Wei J; Zhou Y; Ji W; Liu J; Zhi X; Zhang J
Cell Death Dis; 2015 Dec; 6(12):e2020. PubMed ID: 26673665
[TBL] [Abstract][Full Text] [Related]
20. Effects of PI3K inhibitor NVP-BKM120 on acquired resistance to gefitinib of human lung adenocarcinoma H1975 cells.
Liang YC; Wu HG; Xue HJ; Liu Q; Shi LL; Liu T; Wu G
J Huazhong Univ Sci Technolog Med Sci; 2013 Dec; 33(6):845-851. PubMed ID: 24337846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
